Munich Startup
FarmInsect GmbH

FarmInsect GmbH

Farminsect is an AgTec startup. With Farminsect, we want to revolutionize agriculture by giving farmers the opportunity to produce protein feed for their livestock themselves. Protein feed includes, for example, soy or fish meal....

Founded2026
Business ModelB2B
IndustryBioTech
This content was machine translated.

About FarmInsect GmbH

Farminsect is an AgTec startup. With Farminsect, we want to revolutionize agriculture by giving farmers the opportunity to produce protein feed for their livestock themselves. Protein feed includes, for example, soy or fish meal. Both must be imported to the EU at 90%. Both feed materials create massive ecological problems such as rainforest deforestation and overfishing of the oceans. With Farminsect, we offer farmers a solution to produce insect larvae from regional residual materials, such as crop residues. They can then feed the insect larvae as protein feed to their livestock. This allows farmers to save over 50% of the CO2 emissions from feed production while simultaneously reducing their costs by up to 20%. Farminsect provides farmers with a machine concept that enables automated insect production. Additionally, Farminsect supplies farmers weekly with young larvae. With this approach, the barriers to entry for farmers are minimal.

More like this

Discover relevant articles, startups, and events from the ecosystem

EpiCure

EpiCure is a research project of Ludwig Maximilians University Munich and is scheduled to be incorporated as an independent biotech company in 2026/2027. The focus is on epigenetic therapies, a mechanism of action that still holds considerable untapped potential in oncology. The lead compound is Carbacitabin (CAB), a drug molecule rationally designed on the basis of epigenetic expertise for blood cancer diseases, primarily positioned for high-risk patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CAB was specifically developed to address the weaknesses of clinically used standard therapeutics, and achieves approximately 100-fold reduced toxicity in patient-derived tumor models while simultaneously demonstrating superior efficacy. The regulatory foundation is in place: The BfArM has confirmed the preclinical development program in Scientific Advice. The first clinical trial is planned for 2027/28.

B2BBioTech

2026Founded
-Team size
Seed stage

ProviGenAI

ProviGenAI develops a software platform for automated experiments and data-driven process optimization. Many laboratories and biotechnology development environments already have extensive automation in place, yet the planning, evaluation, and adaptation of experiments continues to be done manually. Our platform combines automated laboratory workflows with AI-based optimization. It translates experimental protocols into executable workflows, orchestrates experiments on existing automation systems, and analyzes the resulting data to continuously improve parameters. This creates closed learning loops between experiment, analysis, and decision-making. Teams can optimize biotechnological processes—such as fermentation, screening, or bioprocess development—significantly faster and more efficiently.

B2BBioTech

2026Founded
-Team size
Seed stage